The science of CBD lags behind its marketing


Treatments for pain and other common health problems often fall short, leading to untold misery and frustration. So it’s not hard to understand the lure of a treatment that promises to be benign, natural and good for just about everything that ails you. Enter cannabidiol, or CBD.
So far, the U.S. Food and Drug Administration has approved only one drug containing the chemical: a treatment for rare and severe forms of epilepsy. But that hasn’t stopped people from trying CBD to relieve arthritis, morning sickness, pain, depression, anxiety, addiction, inflammation and acne. And it hasn’t kept companies from marketing the heck out of CBD-infused anything. It’s the sort of situation that gets us wondering: What’s the science here?

The science is skimpy at best, neuroscience writer Laura Sanders reports in this issue. Clinical trials, some of which included children, were conducted to determine safety and efficacy before the FDA approved

Ga naar Bron